Kunz, Julius Valentin
Hansmann, Helena
Fähndrich, Mareike
Pigorsch, Mareen
Bethke, Nicole
Peters, Harm
Krüger, Anne
Schroeder, Tim
Marcy, Florian
Magomedov, Abakar
Müller-Redetzky, Holger
Eckardt, Kai-Uwe
Khadzhynov, Dmytro
Enghard, Philipp
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 8 March 2024
Accepted: 3 June 2024
First Online: 11 June 2024
Declarations
:
: The authors declare no competing interests.
: The study was approved by the local ethics committee (EA2/101/21). The study protocol can be found in the . The study was registered in the German Registry of Clinical Trials (DRKS00026177). The trial was conducted according to the Declaration of Helsinki.
: Written informed consent was obtained from patients or their legal representatives. For patients incapable of giving consent and without a legal representative, urgent appointment of a legal guardian was requested. At inclusion, the attending physician was asked to confirm patient eligibility.
: Not applicable.
: JVK received honoraria for lectures from NAW Berlin. KUE received honoraria from Astra Zeneca and Bayer for consultancy and lectures, as well as from Akebia and Otsuka for consultancy. DK received fees for speaking at a symposia organized on behalf of Fresenius Medical Care AG, Germany. For all other authors, there are no financial disclosures to declare. PE filed two patents for novel urinary biomarkers outside the submitted work. PE has received grants or contracts from the following entities: Deutsche Forschungsgemeinschaft (DFG), Jackstädt Stiftung, Berliner Institut für Gesundheitsforschung (BIH), Bundesministerium für Bildung und Forschung (BMBF), Investitionsbank Berlin (IBB). Consulting fees include advisory roles for Glaxo Smith Klein (GSK), Bayer, and AstraZeneca. Payment or honoraria for lectures, presentations, speakers bureaus, and educational events were received from Akademie der Nieren, BDI Kickstarter, NAW Berlin, and Nachlese ASN Charité. Support for attending meetings and travel was provided by Nachlese ASN Charité and AstraZeneca. Author PE has participated in an Advisory Board for Otsuka. PE serves as the spokesperson for the committee for intensive care of the German Society of Nephrology (DGfN). Stock or stock options have been received from Gilead.